Cannabidivarin (CBDV) is a rare and lesser-known cannabinoid found in both hemp and cannabis plants. Researchers are currently studying this compound’s therapeutic potential in the treatment of various neurological and psychiatric disorders, including autism spectrum disorder (ASD). While more research is forthcoming, early studies indicate some promise with regard to using CBDV for Autism.
ASD is a complex neurodevelopmental disorder that affects communication, social interaction, and behavior. There is no cure for ASD, and the available treatments mainly focus on managing its symptoms. However, CBDV has emerged as a promising candidate for the treatment of ASD, as it has shown positive effects in preclinical animal models.
Preclinical studies have shown that CBDV may improve social behavior, motor coordination, and short-term memory while reducing irritability and repetitive movements in animal models with ASD. Moreover, CBDV does not have psychoactive effects, unlike THC, which is a psychoactive compound found in the cannabis plant.
Apart from its potential in the treatment of ASD, CBDV is also being investigated for its potential in the treatment of seizures, muscular dystrophy, and attention deficit hyperactivity disorder (ADHD). The US Food and Drug Administration (FDA) has already approved CBD for the treatment of seizures, and ongoing research indicates its potential for treating symptoms of autism.
CBDV is similar to CBD in terms of its potential to improve seizures and stress resilience, and it may normalize brain function and behavior in individuals with ASD. In a recent clinical trial, CBDV was tested on 100 children and adolescents between the ages of 5 and 18 years old who had a diagnosis of ASD. The study aimed to determine the effects of CBDV on irritability, which is a common symptom of ASD.
Animal studies have shown that high doses of CBDV can improve sociability and short-term memory while reducing compulsive self-grooming and repetitive movements in ASD animal models. These findings suggest that CBDV may offer a potential clinical treatment for ASD.
To be certain, the therapeutic potential of CBDV in the treatment of ASD and other neurological disorders is a promising area of research. While more studies are needed to establish the safety and efficacy of CBDV, the ongoing research indicates that it may provide a new avenue for the treatment of ASD and other related disorders. Further research is essential to fully understand the mechanisms underlying the effects of CBDV and to develop safe and effective treatment options for individuals with ASD.
